Status:
ENROLLING_BY_INVITATION
Cardiotoxicity of Cancer Therapy (CCT)
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the inc...
Detailed Description
The overall study objectives are: 1. To determine the longitudinal relationships between circulating markers, such as Neuregulin (NRG)-1Beta levels and incident risk of adverse cardiovascular outcome...
Eligibility Criteria
Inclusion
- Age 18 years or older
- HER-2 positive breast cancer designated to receive trastuzumab chemotherapy with or without prior exposure to anthracycline-based chemotherapy
- Non-HER-2 positive breast cancer designated to receive treatment with an anthracycline-containing regimen
Exclusion
- Other contraindications to trastuzumab or anthracycline chemotherapy.
- Vulnerable populations
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2037
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT01173341
Start Date
July 1 2010
End Date
April 1 2037
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104